Paper Review Records
全部论文审稿周期
27 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
93
天
Pharmacokinetic Interaction Between Eperisone and Ojeok‐San in Healthy Subjects
作者
Do Hoon Keum; Minkyu Choi; Kyoung Hoon Mo; Sukyong Yoon; Min Soo Park; Young Woo Kim; Won‐Yung Lee; Choon Ok Kim展开收起
作者单位
1. Department of Clinical Pharmacology Severance Hospital Yonsei University Health System Seoul Republic of Korea; 2. Department of Pharmaceutical Medicine and Regulatory Sciences Colleges of Medicine and Pharmacy Yonsei University Incheon Republic of Korea; 3. Department of Pediatrics Yonsei University College of Medicine Seoul Republic of Korea; 4. School of Korean Medicine Dongguk University Gyeongju Republic of Korea; 5. School of Korean Medicine Wonkwang University Iksan Republic of Korea展开收起
111
天
Pharmacokinetic and Bioequivalence of Mirtazapine Orally Disintegrating Tablets: A Randomized, Crossover Study
作者
Kai Bin Liew; Kar Ming Yee; Jeyashanthini Nalaiya; Atiqah Amran; Khairil Aswad Othman展开收起
作者单位
1. Department Faculty of Pharmacy University of Cyberjaya (UoC). Cyberjaya Selangor Malaysia; 2. Formulation and R&D Technologies Duopharma Innovation Sdn. Bhd. Shah Alam Selangor Malaysia; 3. Questra Bio‐Clinical Research Centre Questra Clinical Research Sdn. Bhd., Permatang Pauh Pulau Pinang Malaysia展开收起
175
天
A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia
作者
Longxia Chen; Ruilin Ding; Yuanwei Chen; Xinghai Li; Tengqiong Xiong; Hong Chen; Xiaojing Hu; Yi Zhou; Feng Jiang; Qing Peng展开收起
作者单位
1. Institute of Drug Clinical Trial/GCP Center The Affiliated Hospital of Southwest Medical University Luzhou China; 2. Hinova Pharmaceuticals Inc. Chengdu China; 3. Department of Cardiology The Affiliated Hospital of Southwest Medical University Luzhou China展开收起
241
天
A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants
作者
Takakazu Sato; Hiroyuki Fukase; Takaaki Ishida; Arisa Karasawa展开收起
作者单位
1. Chugai Pharmaceutical Co., Ltd. Tokyo Japan; 2. Clinical Research Hospital Tokyo Japan展开收起
277
天
Pharmacokinetic and Pharmacodynamic Bio‐Similarity of ADL‐018 to Innovator Omalizumab: A Randomized Study in Healthy Adults
作者
Sunil Soitawala; Hiren Prajapati; Hiren Mehta; Pawan Kumar Singh展开收起
作者单位
1. Clinical Research Department Veeda Clinical Research Ltd. Mehsana Gujarat India; 2. Clinical Research Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 3. Clinical Affairs/Biometrics Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 4. Kashiv Biosciences, LLC Ahmedabad Gujarat India展开收起
126
天
An Open‐Label Study Investigating the 5‐HT 2A Receptor Occupancy of Remlifanserin (ACP‐204) With the PET Radioligand [ 18 F]Altanserin in Healthy Male Participants
作者
Ethan S. Burstein; Christine Sandiego; Brian Raether; Xiaoshu Feng; Bryan Dirks; Mona Darwish; Peter Zhang; David S. Russell; Eugenii A. Rabiner; Sanjeev Pathak展开收起
作者单位
1. Acadia Pharmaceuticals Inc. San Diego CA USA; 2. Perceptive Discovery New Haven CT USA; 3. Acadia Pharmaceuticals Inc. Princeton NJ USA; 4. Perceptive Discovery London UK展开收起
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
